ShanghaiMay 15, 2026 /PRNewswire/ — Recently, FUJIFILM Holdings Corporation (hereinafter referred to as “FUJIFILM Group”) announced its financial results for the fiscal year 2025 (ending March 31, 2026).
Full-Year Results for Fiscal Year 2025 (Ending March 31, 2026):
- Revenue was 3,357.0 billion yen, up 5.0% year-on-year.
- Operating profit was 350.2 billion yen, up 6.1% year-on-year.
- Net income attributable to FUJIFILM Group was 276.7 billion yen, up 6.0% year-on-year.
- The annual dividend for fiscal year 2025 is expected to be 70 yen per share, marking the 16th consecutive year of annual dividend increases.
Outlook for Fiscal Year 2026 (Ending March 31, 2027):
- For the new fiscal year ending March 31, 2027, driven by the expanded operations of large-scale Bio CDMO facilities and increased sales volumes of semiconductor materials, the company expects financial results for fiscal year 2026 to reach record highs, with projected revenue of 3,470.0 billion yen.
- Supported by strong performance in the Electronic Materials and Imaging business segments, operating profit is expected to increase by 4.2% year-on-year to 365.0 billion yen.
- Net income attributable to FUJIFILM Group is projected to be 280.0 billion yen.
- Due to uncertainties regarding future developments, the outlook does not include the potential impact of fluctuations in raw material prices and energy costs arising from escalating geopolitical tensions in the Middle East.
- The annual dividend for fiscal year 2026 is expected to be 75 yen per share, marking the 17th consecutive year of annual dividend increases.
“In fiscal year 2025, the Group’s revenue, operating profit, and net income all reached record highs, primarily driven by the commencement of operations at new Bio CDMO facilities in the Healthcare business segment, the robust performance of semiconductor materials in the Electronic Materials business, and the steady growth of the Imaging business, including digital cameras,” said Teiichi Goto, Representative Director, President and CEO of FUJIFILM Holdings Corporation. “In this fiscal year, we will focus on achieving sustainable growth by further expanding our semiconductor materials business and increasing the production capacity of our Bio CDMO business. We are committed to accelerating the achievement of the goals set in our medium-term management plan VISION2030, transforming FUJIFILM into a top-tier global business conglomerate.”
Fourth Quarter Performance Highlights by Business Segment
In the fourth quarter (January 1, 2026 to March 31, 2026), revenue increased by 6.8% year-on-year to 927.3 billion yen. Operating profit was 101.8 billion yen, down 4.8% year-on-year. Net income attributable to FUJIFILM Group increased by 5.0% year-on-year to 83.4 billion yen.
Healthcare
- Revenue increased by 5.4% year-on-year to 333.6 billion yen, while operating profit decreased by 34.7% to 29.7 billion yen, primarily due to rising raw material costs from surging silver prices.
- In the Medical Systems business, strong sales of endoscopy products in key markets such as the United States and Europe, along with the concentrated delivery of large-scale contracts, boosted sales by approximately 30%, driving overall revenue growth.
- In the Bio CDMO business, revenue grew thanks to the commencement of operations at new facilities in Denmark; additionally, the Life Science Solutions business achieved revenue growth due to the continued recovery of the cell culture media market.
Electronic Materials
- Revenue increased by 27.4% year-on-year to 127.5 billion yen, and operating profit grew by 74.0% year-on-year to 30.7 billion yen.
- In the Electronic Materials business, strong demand for advanced semiconductor materials used in generative AI drove a 29.3% year-on-year increase in revenue.
- In the High-Performance Materials business, revenue increased by 24.1% year-on-year, supported by excellent sales performance of display materials and growth in sales of high-capacity data tapes to major IT companies.
Imaging
- Driven by strong sales of instant photo systems and digital cameras, revenue increased by 22.6% year-on-year to 141.4 billion yen, and operating profit rose by 1.1% year-on-year to 24.5 billion yen.
- In the Consumer Imaging business, steady sales growth of core instant camera models such as instax™ mini 12 and instax™ mini Evo, along with robust sales of products like instax™ WIDE 400, instax™ Link 3, and instax™ WIDE Evo, expanded the user base and drove revenue growth.
- In the Professional Imaging business, strong performance of new products released in fiscal year 2025, including GFX100RF, X half, X‑E5, and X‑T30 III, combined with continued sales of existing models, contributed to overall revenue growth.
Business Innovation
- Revenue decreased by 3.5% year-on-year to 324.8 billion yen, and operating profit fell by 15.4% year-on-year to 27.0 billion yen.
- In the Business Solutions business, the expansion of digital transformation (DX)-related solutions drove revenue growth.
- In the Office Solutions business, revenue declined due to a sluggish market in the Asia-Pacific region and a strategic reduction in low-margin product lines.
- In the Graphic Communications business, increased sales of digital printing equipment in new markets offset the impact of weak demand for printing plates and related products in the European market, resulting in overall revenue remaining roughly flat.
For more details, please visit the relevant content on the FUJIFILM website: https://ir.fujifilm.com/en/investors/ir-materials/earnings-presentations.html